A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose of IBI3002 in Patients With Asthma - a Randomized, Double-Blind, Placebo-Controlled Study
Latest Information Update: 04 Jul 2025
At a glance
- Drugs IBI 3002 (Primary)
- Indications Asthma
- Focus Adverse reactions
Most Recent Events
- 26 Jun 2025 Status changed from not yet recruiting to recruiting.
- 20 Jun 2025 New trial record